Seattle Genetics (SGEN) Reports Five-Year Survival Results from Phase 1 Trial of ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma
Tweet Send to a Friend
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted final five-year survival results from a phase 1 clinical trial evaluating ADCETRIS (brentuximab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
